Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun PharmaceuticalsBusiness Wire • 01/03/23
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus NephritisBusiness Wire • 11/30/22
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational ResultsBusiness Wire • 11/03/22
Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022Business Wire • 10/28/22
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022Business Wire • 10/27/22
Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022Business Wire • 09/20/22
Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus NephritisBusiness Wire • 09/19/22
Aurinia Pharmaceuticals Inc's (AUPH) CEO Peter Greenleaf on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational ResultsBusiness Wire • 08/04/22
Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022Business Wire • 07/25/22
Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in EuropeBusiness Wire • 07/22/22
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and PerformanceBusiness Wire • 07/14/22